Prevalence of hypercalcitoninemia in patients on maintenance dialysis referred to kidney transplantation

Clinical Nephrology

Volumn 71, Issue 5, 2009, Pages 538-542

  Akan, B ^a   Bohmig G ^a   Sunder Plassmann, G ^a   Borchhardt, Kyra A ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

C cell hyperplasia; Calcitonin prevalence; Chronic kidney disease; Dialysis

Indexed keywords

CALCITONIN; TUMOR MARKER;

ABNORMAL SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ARTICLE; CALCITONIN BLOOD LEVEL; CHRONIC KIDNEY DISEASE; FEMALE; HEMODIALYSIS; HUMAN; HYPERCALCITONINEMIA; KIDNEY TRANSPLANTATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; PREVALENCE; SEX DIFFERENCE; THYROID HYPERPLASIA; THYROID PARAFOLLICULAR CELL HYPERPLASIA; THYROIDECTOMY; AUSTRIA; BLOOD; CHEMOLUMINESCENCE; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; MEDULLARY CARCINOMA; METHODOLOGY; MIDDLE AGED; PROGNOSIS; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; THYROID TUMOR;

AUSTRIA; CALCITONIN; CARCINOMA, MEDULLARY; CHEMILUMINESCENT MEASUREMENTS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; THYROIDECTOMY; TUMOR MARKERS, BIOLOGICAL;

EID: 67649411872     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP71538     Document Type: Article

References (11)

1. Borchhardt KA, Heinzl H, Gessl A, Hörl WH, Kaserer K, Sunder-Plassmann G. Calcitonin concentrations in patients with chronic kidney disease and medullary thyroid carcinoma or C-cell hyperplasia. Kidney Int. 2006; 70: 2014-2020.
2. Borchhardt KA, Hörl WH, Sunder-Plassmann G. Reversibility of "secondary hypercalcitoninemia" after kidney transplantation. Am J Transplant. 2005; 5: 1757-1763.
3. Davis NS, DiSant'Agnese PA, Ewing JF, Mooney RA. The neuroendocrine prostate: characterization and quantitation of calcitonin in the human gland. J Urol. 1989; 142: 884-888.
4. Escalada J, Teruel JL, Pavon I, Vila T, Navarro J, Varela C. Normal calcitonin response to pentagastrin stimulation in patients with chronic renal failure. Acta Endocrinol (Copenh). 1993; 129: 39-41.
5. Fraser LR, Osiguwa OO. Human sperm responses to calcitonin, angiotensin II and fertilization-promoting peptide in prepared semen samples from normal donors and infertility patients. Hum Reprod. 2004; 19: 596-606.
6. Hurley DL, Tiegs RD, Wahner HW, Heath H, 3rd. Axial and appendicular bone mineral density in patients with long-term deficiency or excess of calcitonin. N Engl J Med. 1987; 317: 537-541.
7. Kotzmann H, Schmidt A, Scheuba C, Kaserer K, Watschinger B, Soregi G, Niederle B, Vierhapper H. Basal calcitonin levels and the response to pentagastrin stimulation in patients after kidney transplantation or on chronic hemodialysis as indicators of medullary carcinoma. Thyroid 1999; 9: 943-947.
8. Lissak B, Baudin E, Cohen R, Barbot N, Meyrier A, Niccoli P, Bouyge N, Modigliani E. Pentagastrin testing in patients with renal insufficiency: normal responsivity of mature calcitonin. Thyroid. 1998; 8: 265-268.
9. Meyrier A. What level of serum calcitonin indicates medullary thyroid carcinoma in patients with chronic kidney disease? Nat Clin Pract Nephrol. 2007; 3: 246-247.
10. Mirzaei S, Krotla G, Knoll P, Koriska K, Kohn H. Possible effect of calcitonin deficiency on bone mass after subtotal thyroidectomy. Acta Med Austriaca. 1999; 26: 29-31.
11. Stevenson JC, Hillyard CJ, MacIntyre I, Cooper H, Whitehead MI. A physiological role for calcitonin: protection of the maternal skeleton. Lancet. 1979; 2: 769-770.